$VIRX
Viracta Therapeutics, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020054194 Filed on November 16, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q4 2019 Q3
Revenue $0.00 $2.070M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.320M $2.480M $2.510M
YoY Change -7.57% 0.81% -6.69%
% of Gross Profit
Research & Development $3.105M $4.950M $3.534M
YoY Change -12.14% 50.0% -1.56%
% of Gross Profit
Depreciation & Amortization $10.00K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $3.992M $7.430M $3.534M
YoY Change 12.96% 28.99% -43.73%
Operating Profit -$3.992M
YoY Change
Interest Expense $66.00K -$70.00K -$70.00K
YoY Change -194.29% -76.67% -75.86%
% of Operating Profit
Other Income/Expense, Net $22.00K $140.0K $170.0K
YoY Change -87.06% 133.33% 183.33%
Pretax Income -$4.640M -$5.290M -$5.940M
YoY Change -21.89% -11.83% -8.76%
Income Tax
% Of Pretax Income
Net Earnings -$4.079M -$5.290M -$5.942M
YoY Change -31.35% -11.83% -8.73%
Net Earnings / Revenue -255.56%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.020M -$1.658M -$1.980M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.00M $29.10M $32.80M
YoY Change -20.73% 112.41% 62.38%
Cash & Equivalents $11.91M $18.22M $19.70M
Short-Term Investments $0.00 $16.40M $13.10M
Other Short-Term Assets $1.600M $7.200M $7.700M
YoY Change -79.22% 380.0% 492.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $27.62M $36.32M $40.50M
YoY Change -31.79% 138.96% 88.37%
LONG-TERM ASSETS
Property, Plant & Equipment $400.0K $3.000K $1.000M
YoY Change -60.0% -72.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $98.00K $100.0K
YoY Change -100.0% -13.27% -7.41%
Total Long-Term Assets $409.0K $918.0K $1.100M
YoY Change -62.82% 640.32% 1179.07%
TOTAL ASSETS
Total Short-Term Assets $27.62M $36.32M $40.50M
Total Long-Term Assets $409.0K $918.0K $1.100M
Total Assets $28.03M $37.24M $41.60M
YoY Change -32.61% 143.02% 92.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $150.0K $791.0K $800.0K
YoY Change -81.25% -43.22% -37.35%
Accrued Expenses $3.400M $3.200M $2.700M
YoY Change 25.93% 28.0% -27.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $5.500M $5.500M
YoY Change -100.0% -25.68% -24.66%
Total Short-Term Liabilities $3.567M $9.416M $8.900M
YoY Change -59.92% -16.84% -27.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $9.000K $13.00K
YoY Change -100.0% 12.5% 225.0%
Total Long-Term Liabilities $0.00 $9.000K $13.00K
YoY Change -100.0% 12.5% 225.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.567M $9.416M $8.900M
Total Long-Term Liabilities $0.00 $9.000K $13.00K
Total Liabilities $3.567M $9.697M $9.316M
YoY Change -61.71% -14.42% -24.2%
SHAREHOLDERS EQUITY
Retained Earnings -$699.6M -$682.8M
YoY Change 3.54%
Common Stock $2.000K $1.000K $11.00K
YoY Change -81.82% -75.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$40.81M -$28.38M $32.29M
YoY Change
Total Liabilities & Shareholders Equity $28.03M $37.24M $41.60M
YoY Change -32.61% 143.02% 92.59%

Cashflow Statement

Concept 2020 Q3 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$4.079M -$5.290M -$5.942M
YoY Change -31.35% -11.83% -8.73%
Depreciation, Depletion And Amortization $10.00K
YoY Change 0.0%
Cash From Operating Activities -$4.240M -$3.750M -$5.430M
YoY Change -21.92% -42.31% -0.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$3.210M -$10.69M
YoY Change -100.0% -414.41%
Cash From Investing Activities $0.00 -$3.210M -$10.69M
YoY Change -100.0% -414.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.140M -10.00K 26.06M
YoY Change -72.6% -125.0% 403.09%
NET CHANGE
Cash From Operating Activities -4.240M -3.750M -5.430M
Cash From Investing Activities 0.000 -3.210M -10.69M
Cash From Financing Activities 7.140M -10.00K 26.06M
Net Change In Cash 2.900M -6.970M 9.940M
YoY Change -70.82% 7.89% 217.57%
FREE CASH FLOW
Cash From Operating Activities -$4.240M -$3.750M -$5.430M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1576000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
409000
CY2020Q3 us-gaap Assets
Assets
28033000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
150000
CY2020Q3 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
380000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
901000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1727000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5465000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
409000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
545000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3567000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
272000
CY2020Q3 us-gaap Liabilities
Liabilities
3567000
CY2019Q4 us-gaap Liabilities
Liabilities
9697000
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
5545000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
11769000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
718522000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
698572000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-699603000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
24466000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
27543000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28033000
dei Entity File Number
EntityFileNumber
000-51531
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3295878
dei Entity Address Address Line1
EntityAddressAddressLine1
395 Oyster Point Boulevard
CY2020Q3 us-gaap Assets Current
AssetsCurrent
27624000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16364000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1697000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
36322000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
817000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
98000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12761000
dei City Area Code
CityAreaCode
650
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei Local Phone Number
LocalPhoneNumber
266-3500
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Trading Symbol
TradingSymbol
SNSS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26048000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
5500000
CY2019Q4 us-gaap Assets
Assets
37240000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
791000
CY2019Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
521000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
985000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1109000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9416000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-682800000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37240000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3534000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10128000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
114000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-5942000
us-gaap Net Income Loss
NetIncomeLoss
-16803000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16804000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12748000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.32
us-gaap Profit Loss
ProfitLoss
-16803000
us-gaap Profit Loss
ProfitLoss
-18043000
us-gaap Share Based Compensation
ShareBasedCompensation
1106000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
-41000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
6000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
35000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-219000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
721000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-641000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-623000
snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-141000
snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
44000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-84000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
234000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
574000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-722000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15776000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18437000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
747000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
13080000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
17154000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16407000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13080000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5453000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5500000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7500000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
12533000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12633000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7156000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32068000
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
464000
snss Proceeds From Exercise Of Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights
23000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7787000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18261000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6224000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
16106000
CY2020Q3 snss Issuance Of Common And Preferred Stock In Underwritten Offering Net Of Issuance Costs
IssuanceOfCommonAndPreferredStockInUnderwrittenOfferingNetOfIssuanceCosts
12598000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
400000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
11739000
CY2019Q3 snss Issuance Of Common And Preferred Stock In Underwritten Offering Net Of Issuance Costs
IssuanceOfCommonAndPreferredStockInUnderwrittenOfferingNetOfIssuanceCosts
26032000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
32294000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
23000
snss Issuance Of Common And Preferred Stock In Underwritten Offering Net Of Issuance Costs
IssuanceOfCommonAndPreferredStockInUnderwrittenOfferingNetOfIssuanceCosts
12598000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1106000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3993000
snss Issuance Of Common And Preferred Stock In Underwritten Offering Net Of Issuance Costs
IssuanceOfCommonAndPreferredStockInUnderwrittenOfferingNetOfIssuanceCosts
44568000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
54000
snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
464000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
36000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1222000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s condensed consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to <font style="color:#000000;">valuation of marketable securities, equity and related instruments, revenue recognition, stock-based compensation and clinical trial accounting</font>. </p>
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2493000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1803000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2493000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
26656000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
26657000
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10293000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10293000
CY2020Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.30
CY2020Q3 us-gaap Severance Costs1
SeveranceCosts1
200000
CY2019Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
16363000
CY2019Q4 snss Marketable Securities Gross Unrealized Gains
MarketableSecuritiesGrossUnrealizedGains
1000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2019 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
465000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1106000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1276000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
500000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
147000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
294000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
441000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
32000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
409000
CY2020Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2019Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000

Files In Submission

Name View Source Status
0001564590-20-054194-index-headers.html Edgar Link pending
0001564590-20-054194-index.html Edgar Link pending
0001564590-20-054194.txt Edgar Link pending
0001564590-20-054194-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gqrhbcpv5wao000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10q_20200930.htm Edgar Link pending
snss-20200930.xml Edgar Link completed
snss-20200930.xsd Edgar Link pending
snss-20200930_cal.xml Edgar Link unprocessable
snss-20200930_def.xml Edgar Link unprocessable
snss-20200930_lab.xml Edgar Link unprocessable
snss-20200930_pre.xml Edgar Link unprocessable
snss-ex311_6.htm Edgar Link pending
snss-ex321_8.htm Edgar Link pending